Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions.
Yuichi MitaniMitsuteru HiwatariMasafumi SekiMayumi HangaiJunko TakitaPublished in: International journal of hematology (2019)
Patients with acute myeloid leukemia (AML) co-expressing NUP98/NSD1 and FLT3/ITD have a dismal prognosis despite undergoing hematopoietic stem cell transplantation (HSCT). There are a few studies on successful treatment of relapsed AML co-expressing NUP98/NSD1 and FLT3/ITD. We report a refractory case of molecular relapse of AML co-expressing NUP98/NSD1 and FLT3/ITD post-matched sibling HSCT. Donor lymphocyte infusion (DLI) at an early stage of post-transplantation resulted in complete molecular remission for 29 months with durable chronic graft-versus-host disease. Our case suggests the clinical efficacy of preemptive DLI following minimal residual disease analysis for the treatment of refractory AML.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- early stage
- low dose
- peripheral blood
- squamous cell carcinoma
- stem cells
- single molecule
- acute lymphoblastic leukemia
- wild type
- mesenchymal stem cells
- systemic lupus erythematosus
- cell therapy
- lymph node
- free survival
- combination therapy
- sentinel lymph node
- rectal cancer
- smoking cessation